deltatrials

Recurrent primary peritoneal carcinoma Trials in Hartford, United States

Conditions / Recurrent primary peritoneal carcinoma / Hartford, United States

Clinical trials for Recurrent primary peritoneal carcinoma investigate a range of treatment strategies and patient populations.

18 total trials for this combination

Showing top 10 of 18 trials

Trials

NCT ID Title Status Phase
NCT02839707 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ACTIVE_NOT_RECRUITING
NCT00954174 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer UNKNOWN PHASE3
NCT02446600 Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ACTIVE_NOT_RECRUITING
NCT00888615 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer COMPLETED PHASE2
NCT01372787 Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer UNKNOWN
NCT02446600 Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ACTIVE_NOT_RECRUITING
NCT02502266 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer ACTIVE_NOT_RECRUITING
NCT00897442 Collecting Tumor Samples From Patients With Gynecological Tumors COMPLETED
NCT02502266 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer ACTIVE_NOT_RECRUITING
NCT00565851 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer ACTIVE_NOT_RECRUITING PHASE3

Related Pages